| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MAP/microtubule affinity-regulating kinase 4, MAP/microtubule affinity-regulating kinase-like 1, MARK4, KIAA1860, MARKL1 |
| Entrez GeneID | 57787 |
| WB Predicted band size | 82.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This MARK4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 611-641 amino acids from the C-terminal region of human MARK4. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于MARK4抗体的参考文献及其摘要概览：
1. **"MARK4 regulates microtubule dynamics and Alzheimer’s disease pathogenesis via tau phosphorylation"**
*作者: Li G, et al. (2016)*
摘要：该研究通过特异性MARK4抗体验证了MARK4在阿尔茨海默病模型中的表达上调，证实其通过磷酸化tau蛋白促进神经纤维缠结的形成，并揭示了MARK4作为潜在治疗靶点的可能性。
2. **"Development and characterization of a high-affinity monoclonal antibody against human MARK4 for cancer diagnostics"**
*作者: Sharma P, et al. (2019)*
摘要：研究团队开发了一种针对人源MARK4的单克隆抗体，验证了其在ELISA、Western blot及免疫组化中的高特异性，并发现MARK4在多种癌细胞系中高表达，提示其作为癌症生物标志物的潜力。
3. **"Inhibition of MARK4 disrupts microtubule stability and suppresses glioblastoma progression"**
*作者: Chen X, et al. (2021)*
摘要：利用抗MARK4抗体进行功能研究，发现抑制MARK4活性可破坏胶质母细胞瘤的微管稳定性，诱导细胞周期停滞和凋亡，表明靶向MARK4可能成为神经肿瘤治疗的新策略。
4. **"MARK4 antibody-based detection reveals its role in insulin resistance and obesity"**
*作者: Kumar R, et al. (2018)*
摘要：通过MARK4特异性抗体检测，发现肥胖小鼠模型中MARK4表达显著升高，其通过干扰胰岛素信号通路加剧代谢紊乱，提示MARK4与糖尿病及肥胖的病理关联。
(注：以上文献名为示例性内容，实际文献需根据具体数据库检索确认。)
The MARK4 (Microtubule Affinity-Regulating Kinase 4) antibody is a crucial tool for studying the serine/threonine kinase MARK4. a member of the PAR1 (Partitioning Defective 1) family involved in regulating cell polarity, microtubule dynamics, and intracellular signaling. Discovered in the late 1990s, MARK4 gained attention for its role in phosphorylating microtubule-associated proteins (e.g., tau, MAP2), destabilizing microtubules, and influencing neuronal development and function. Dysregulation of MARK4 is linked to neurodegenerative diseases, including Alzheimer’s and Parkinson’s, where hyperphosphorylated tau aggregates into neurofibrillary tangles. It also intersects with metabolic disorders and cancer via pathways like Wnt/β-catenin and AMPK/mTOR.
MARK4 antibodies are generated using immunogens such as recombinant proteins or synthetic peptides corresponding to specific regions (e.g., kinase domain). They enable detection of MARK4 expression, localization, and interactions in techniques like Western blot, immunofluorescence, and IP. Commercial antibodies (e.g., from Cell Signaling, Abcam) are validated for specificity across human, mouse, and rat models. Research using these antibodies has revealed MARK4's splice variants, tissue-specific _expression (high in brain, testis), and stress-responsive upregulation.
Current studies focus on MARK4 inhibitors as potential therapeutics for tauopathies. The antibody remains vital for unraveling MARK4’s pathophysiological roles and drug discovery.
×
